CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Alliance revenues	[1]	$ 2,067	$ 1,967	$ 4,240	$ 4,028
Total revenues		13,283	13,007	28,162	31,492
Costs and expenses:
Cost of sales	[2]	3,300	3,237	6,679	8,122
Selling, informational and administrative expenses	[2]	3,717	3,497	7,212	6,914
Research and development expenses	[2]	2,696	2,648	5,189	5,153
Acquired in-process research and development expenses		6	33	6	55
Amortization of intangible assets		1,307	1,184	2,615	2,287
Restructuring charges and certain acquisition-related costs		1,254	214	1,356	222
Other (income)/deductions––net		1,107	(75)	1,787	200
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[3]	(103)	2,269	3,318	8,539
Provision/(benefit) for taxes on income/(loss)		(134)	(71)	159	644
Income from continuing operations		31	2,340	3,159	7,895
Discontinued operations––net of tax		17	(2)	12	(1)
Net income before allocation to noncontrolling interests		48	2,338	3,171	7,894
Less: Net income attributable to noncontrolling interests		7	11	15	24
Net income attributable to Pfizer Inc. common shareholders		$ 41	$ 2,327	$ 3,156	$ 7,870
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 0.01	$ 0.41	$ 0.56	$ 1.40
Discontinued operations––net of tax (in dollars per share)		0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		0.01	0.41	0.56	1.40
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		0.01	0.41	0.55	1.38
Discontinued operations––net of tax (in dollars per share)		0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 0.01	$ 0.41	$ 0.55	$ 1.38
Weighted-average shares--basic (in shares)		5,666	5,646	5,662	5,640
Weighted-average shares--diluted (in shares)		5,696	5,713	5,696	5,720
Product revenues
Revenues	[1]	$ 10,871	$ 10,766	$ 23,314	$ 26,988
Royalty revenues
Revenues	[1]	$ 345	$ 273	$ 608	$ 477

[1] See Note 1A.

[2] Exclusive of amortization of intangible assets.

[3] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). As described above, in connection with the organizational changes effective in the first quarter of 2024, costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations and overhead costs associated with our manufacturing operations are now included in Biopharma’s earnings. We have reclassified $2.0 billion and $3.4 billion of net costs in the second quarter and first six months of 2023, respectively, from Other business activities to Biopharma to conform to the current period presentation.